William Finlay

William Finlay has a diverse work experience that spans over two decades. William is currently serving as the President of the LockBody Program at Centessa Pharmaceuticals since March 2023. Prior to this, they co-founded Granular Therapeutics in 2021 and was also a co-founder at ULTRAHUMAN LIMITED in 2016.

Before their entrepreneurial endeavors, William worked at mAbs Journal as an Associate Editor starting from January 2015. William also founded and served as the CEO of LockBody Therapeutics, a Centessa company, from April 2017 to March 2023.

Furthermore, William was a Scientific Advisory Board Member at Scholar Rock from July 2020 to November 2022. William gained valuable industry experience at Pfizer, where they held the positions of Senior Director from April 2015 to January 2016, and Director from November 2011 to April 2015. Additionally, they worked as a Principal Scientist at Wyeth Biotech from May 2006 to September 2009.

William's early career includes roles such as Senior Post-Doctoral Researcher at Dublin City University from January 2004 to April 2006 and Post-Doctoral Researcher at NIH CBER-FDA from January 2001 to January 2004. William'sextensive work history highlights their experience and expertise in the pharmaceutical and biotech industry.

William Finlay completed their education from 1993 to 2001 at Glasgow Caledonian University, where they obtained a PhD in Microbiology and Biochemistry. Prior to that, they attended Regent House Grammar School, although the specific dates and degree obtained are unknown.